The research of Andrew H. Limper, M.D., explores how the lungs defend against and eliminate fungal infections, such as pneumocystis pneumonia, in people with impaired defense systems. Lung infections, called pneumonias, are particularly life-threatening in people with weakened host immunity.

Dr. Limper and his team find new ways, beyond traditional antibiotics, to prevent and fight lung infections in these individuals. Research approaches include molecular analysis, applied immunology, cellular and animal models of infection, and studies of human infections.

Additionally, his research interests focus on interstitial lung diseases and pulmonary fibrosis. Dr. Limper’s laboratory team studies the causes and mechanisms of pulmonary fibrosis to identify new combinations of medicines that may be beneficial for people with these disorders. His studies of pulmonary fibrosis also employ large real-world data analysis, radiological imaging and artificial intelligence approaches. These methods facilitate earlier accurate diagnosis and appropriate treatment of people with these disorders.